DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Delirium Prevention in Critically Ill Patients

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Delirium

Phase: N/A

Status: Completed

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Peter Pickkers, MD, PhD, Principal Investigator, Affiliation: Radboud University

Summary

Haloperidol is prescribed in high risk ICU patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model PRE-DELIRIC, or patients with history of dementia or alcohol abuse)since the delirium protocol is changed and haloperidol is added as a prevention treatment we are gathering information what the effect is on several aspects of delirium

Clinical Details

Official title: Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium

Study design: Observational Model: Case Control

Primary outcome: Delirium incidence

Secondary outcome:

duration of delirium days on mechanical ventilator Length of stay in the ICU and in-hospital in-hospital mortality incidence of unplanned removal of tube incidence of delirium subtypes

Effect haloperidol on biomarkers

Detailed description: Measurement the effect of haloperidol as delirium preventive intervention. Determining effect on:

- delirium incidence in the ICU - different subtypes of delirium - delirium free days in 28

days - days on the ventilator - length of stay on the ICU and In-Hospital - 28-day mortality

- incidence of unexpected removal of tubes, and effect between different groups of patients.

Safety of haloperidol concerning QT-time, extrapyramidal symptoms. Data are compared with the data of a historical cohort

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients With Predicted Delirium Chance of >50% or history of dementia or alcohol

abuse and treated with haloperidol Exclusion Criteria:

- CAM-ICU is Not Applicable

- Patients Admitted 24hours or Shorter on the ICU, Patients Who Are Delirious Within 24

Hours After ICU Admission

- patients whereby haloperidol is contra-indicated

Locations and Contacts

Radboud University Nijmegen Medical Centre, Nijmegen 6500HB, Netherlands
Additional Information

Starting date: August 2010
Last updated: August 9, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017